Prediction of the pharmacokinetics of cefodizime and cefotetan in humans from pharmacokinetic parameters in animals. 1990

H Matsushita, and H Suzuki, and Y Sugiyama, and Y Sawada, and T Iga, and M Hanano, and Y Kawaguchi
Faculty of Pharmaceutical Sciences, University of Tokyo, Japan.

Pharmacokinetic behavior of beta-lactam antibiotics (cefodizime and cefotetan) in humans were predicted from the animal data. Total body clearance (CLp) of these drugs in humans (weighting 65-69 kg) were successfully extrapolated from the allometric relationship between the clearance for the unbound drug in plasma and body weight (r = 0.954-1.000) with a power of 0.948-0.991 for cefodizime and 0.700-0.756 for cefotetan. We also predicted the volume of distribution at steady state (Vdss), the volume of distribution in the central compartment (V1) and the volume of distribution at beta-phase (Vd beta) of these drugs in humans from the observed human plasma unbound fraction, inasmuch as the plasma unbound fraction correlated well (r = 0.913-0.995) with the values of Vdss, V1, and Vd beta among various animal species. Based on these predicted pharmacokinetic parameters, we calculated the plasma concentration profiles of these drugs in humans and found a good agreement between the predicted and observed values. We also report here that the prediction is successful when we consider the plasma protein binding of these drugs.

UI MeSH Term Description Entries
D008297 Male Males
D008813 Mice, Inbred ICR An inbred strain of mouse that is used as a general purpose research strain, for therapeutic drug testing, and for the genetic analysis of CARCINOGEN-induced COLON CANCER. Mice, Inbred ICRC,Mice, ICR,Mouse, ICR,Mouse, Inbred ICR,Mouse, Inbred ICRC,ICR Mice,ICR Mice, Inbred,ICR Mouse,ICR Mouse, Inbred,ICRC Mice, Inbred,ICRC Mouse, Inbred,Inbred ICR Mice,Inbred ICR Mouse,Inbred ICRC Mice,Inbred ICRC Mouse
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D001798 Blood Proteins Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins. Blood Protein,Plasma Protein,Plasma Proteins,Serum Protein,Serum Proteins,Protein, Blood,Protein, Plasma,Protein, Serum,Proteins, Blood,Proteins, Plasma,Proteins, Serum
D002439 Cefotaxime Semisynthetic broad-spectrum cephalosporin. Benaxima,Biosint,Cefotaxim,Cefotaxime Sodium,Cefradil,Cephotaxim,Claforan,Fotexina,HR-756,Kendrick,Klaforan,Primafen,Ru-24756,Taporin,HR 756,HR756,Ru 24756,Ru24756,Sodium, Cefotaxime
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013045 Species Specificity The restriction of a characteristic behavior, anatomical structure or physical system, such as immune response; metabolic response, or gene or gene variant to the members of one species. It refers to that property which differentiates one species from another but it is also used for phylogenetic levels higher or lower than the species. Species Specificities,Specificities, Species,Specificity, Species
D015313 Cefotetan A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms. Apacef,Apatef,Cefotan,Cefotetan Disodium,Cefotetan Disodium Salt,Ceftotan,ICI-156834,YM-09330,Disodium Salt, Cefotetan,Disodium, Cefotetan,ICI 156834,ICI156834,Salt, Cefotetan Disodium,YM 09330,YM09330

Related Publications

H Matsushita, and H Suzuki, and Y Sugiyama, and Y Sawada, and T Iga, and M Hanano, and Y Kawaguchi
June 1984, Journal of pharmacokinetics and biopharmaceutics,
H Matsushita, and H Suzuki, and Y Sugiyama, and Y Sawada, and T Iga, and M Hanano, and Y Kawaguchi
December 1982, Antimicrobial agents and chemotherapy,
H Matsushita, and H Suzuki, and Y Sugiyama, and Y Sawada, and T Iga, and M Hanano, and Y Kawaguchi
August 1989, Arzneimittel-Forschung,
H Matsushita, and H Suzuki, and Y Sugiyama, and Y Sawada, and T Iga, and M Hanano, and Y Kawaguchi
June 1983, Journal of pharmacokinetics and biopharmaceutics,
H Matsushita, and H Suzuki, and Y Sugiyama, and Y Sawada, and T Iga, and M Hanano, and Y Kawaguchi
December 1991, Journal of pharmaceutical sciences,
H Matsushita, and H Suzuki, and Y Sugiyama, and Y Sawada, and T Iga, and M Hanano, and Y Kawaguchi
August 1984, The Journal of antibiotics,
H Matsushita, and H Suzuki, and Y Sugiyama, and Y Sawada, and T Iga, and M Hanano, and Y Kawaguchi
January 1992, Infection,
H Matsushita, and H Suzuki, and Y Sugiyama, and Y Sawada, and T Iga, and M Hanano, and Y Kawaguchi
January 1982, Farmakologiia i toksikologiia,
H Matsushita, and H Suzuki, and Y Sugiyama, and Y Sawada, and T Iga, and M Hanano, and Y Kawaguchi
January 2012, Methods in molecular biology (Clifton, N.J.),
H Matsushita, and H Suzuki, and Y Sugiyama, and Y Sawada, and T Iga, and M Hanano, and Y Kawaguchi
November 1990, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!